In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

has announced the U.S. Food and Drug Administration's approval of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adult patients with ...

(RTTNews) - Pfizer Inc. (PFE) Wednesday announced the FDA approval of its supplemental Biologics License Application or sBLA for ADCETRIS otherwise known as brentuximab vedotin combined with ...

The company already has two other cancer drugs approved – Adcetris (brentuximab vedotin) for certain forms of lymphoma and Padcev (enfortumab vedotin) for advanced bladder cancer. The FDA had ...

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with ...

1. The FDA has approved a supplemental Biologics License Application for brentuximab vedotin (Adcetris, Seagen Inc.), in combination with lenalidomide and rituximab, for adults with relapsed or ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...